Showing 3841-3850 of 10110 results for "".
It's All About Relationships
https://practicaldermatology.com/topics/practice-management/its-all-about-relationships/20711/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21109/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21123/Rafael Nunes, MD on LightSheer Duet and AcuPulse
https://practicaldermatology.com/topics/general-topics/rafael-nunes-md-on-lightsheer-duet-and-acupulse/19284/New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21573/New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21633/- Accure Acne, Inc. Appoints Jeffrey O'Donnell, Sr. to the Boardhttps://practicaldermatology.com/news/accure-acne-inc-announces-the-appointment-of-jeffrey-odonnell-sr-to-the-board/2460918/Jeffrey O'Donnell, Sr. has joined Accure Acne's Board of Directors. Along with Chairman and Founder Christopher Carlton and Founder Ed Barbera, Mr. O'Donnell provides strategic guidance for Accure's i
- Biofrontera Appoints Jeffrey Holm as VP of Marketinghttps://practicaldermatology.com/news/biofrontera-appoints-jeffrey-holm-as-vp-of-marketing/2458013/Biofrontera AG, which specializes in the treatment of sun-induced skin cancer, has appointmented Jeffrey Holm as Vice President of Marketing, to further strengthen its US commercialization activities.
- FDA Approves Poteligeo for Cutaneous T-Cell Lymphomashttps://practicaldermatology.com/news/fda-approves-poteligeo-for-cutaneous-t-cell-lymphomas/2457657/The FDA approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with two types of cutaneous T-cell lymphoma (CTCL)—relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This a
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <